NervGen Pharma Corp. (9UA)
Market Closed
17 Jul, 20:00
XDUS 
€
1. 36
-0.06
-4.2254%
€
- Market Cap
- P/E Ratio
- Div Yield
1,203 Volume
0 Eps
€ 1.42
Previous Close Want to track 9UA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NervGen Pharma Corp. (9UA) Statistics
Valuation metrics
Market Cap -
Enterprise value -22.06M
Trailing P/E (ttm) -3.74
Forward P/E -
PEG ratio 0.06
Price/Sales (ttm) -
Price/Book (mrq) 52.4
Enterprise Value/Revenue -
Enterprise Value/EBITDA 3.9
Overview
Shares outstanding 72.33M
Float -
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 50
Average volume (90 days) 17
Price summary
52-Week low 1.36
52-Week high 5.05
Beta -
50-Day moving average 3.28
200-Day moving average 3.09
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Mar 2026
Profitability
Profit margin -
Operating margin -
Operational effectiveness
Return on assets -1.9%
Return on equity -12.69%
Income Statement
Revenue (ttm) -
Revenue per share (ttm) -
Quarterly revenue growth (yoy) -
Gross profit (ttm) -
EBITDA -
Net income to common (ttm) -44.12M
Diluted EPS (ttm) -0.61
Quarterly earnings growth (yoy) -
Balance Sheet
Total cash (mrq) -
Total cash per share (mrq) -
Total debt (mrq) 8.37K
Total Debt/Equity (mrq) 0
Current ratio (mrq) 1.16%
Book value per share (mrq) 0.04
Cash Flow
Cash flow statement -38.33M
Levered free cash flow (LFCF) -44.12M
